Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications

Link to article at PubMed

Environ Sci Pollut Res Int. 2021 Jan 15. doi: 10.1007/s11356-020-12200-1. Online ahead of print.


The outbreak of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the entire world with its infectious spread and mortality rate. The severe cases of coronavirus disease 2019 (COVID-19) are characterized by hypoxia and acute respiratory distress syndrome. In the absence of any specific treatment, just the preventive and supportive care options are available. Therefore, much focus is given to assess the available therapeutic options not only to avoid acute respiratory failure and hypoxia but also to reduce the viral load to control the severity of the disease. The antimalarial drug hydroxychloroquine (HCQ) is among the much-discussed drugs for the treatment and management of COVID-19 patients. This article reviews the therapeutic potential of HCQ in the treatment of COVID-19 based on the available in vitro and clinical evidence, current status of registered HCQ-based clinical trials investigating therapeutic options for COVID-19, and environmental implications of HCQ.

PMID:33447984 | DOI:10.1007/s11356-020-12200-1

Leave a Reply

Your email address will not be published. Required fields are marked *